Latest Breaking News On - Pharmaceuticals company profile - Page 7 : comparemela.com

Mizuho Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $21 00

Mizuho Cuts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $21 00
tickerreport.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tickerreport.com Daily Mail and Mail on Sunday newspapers.

United statesBrendan teehanStephen davisPharmaceuticals stock performanceAcadia pharmaceuticalsNeedham companyCharles schwab investment management incQube research technologies ltdSecurities exchange commissionNorthern trust corpJpmorgan chase coPharmaceuticals incRoyal bankPharmaceuticals dailyPharmaceuticals company profileMutual of america capital management

ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results, Beats Expectations By $0 06 EPS

ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results, Beats Expectations By $0 06 EPS
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United statesJames kiharaStifel nicolausBrendan teehanSecurities exchange commissionPharmaceuticals company profilePharmaceuticals incPharmaceuticals dailyAcadia pharmaceuticalsPharmaceuticals trading downRoyal bankGet free reportTrading downExchange commission

TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Tuesday

TRACON Pharmaceuticals (TCON) Scheduled to Post Earnings on Tuesday
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United statesTracon pharmaceuticalsPharmaceuticals dailyPharmaceuticals stock downPharmaceuticals incPharmaceuticals company profileGet free reportStock down

Oppenheimer Reiterates Market Perform Rating for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Oppenheimer reiterated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $19.00 target price on the biopharmaceutical company’s stock. ACAD has been the topic of a number of other research reports. JPMorgan Chase & Co. decreased their price […]

United statesRobertw bairdBrendan teehanStephen davisQuest partnersPharmaceuticals dailyPharmaceuticals trading downRoyal bankSecurities exchange commissionLegato capital managementChina universal asset management coPharmaceuticals incJpmorgan chase coAcadian asset managementPharmaceuticals company profileFree report

ACADIA Pharmaceuticals (ACAD) Market Perform Rating Reaffirmed at Oppenheimer

Oppenheimer restated their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report released on Monday, Benzinga reports. The brokerage currently has a $19.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also recently commented on ACAD. Mizuho cut shares of ACADIA Pharmaceuticals from […]

United statesZurcher kantonalbank zurich cantonalbankJames kiharaStephen davisMirae asset global investments coMorgan stanleyPharmaceuticals stock downPharmaceuticals incPharmaceuticals company profileEmerald mutual fund advisersRaymond james associatesPharmaceuticals dailyEmerald advisersRoyal bankFree reportModerate buy